NCT04133987View on ClinicalTrials.gov

Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan

PHASE2CompletedINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

April 30, 2020

Study Completion Date

September 30, 2022

Conditions
Dengue
Interventions
BIOLOGICAL

Tetravalent live attenuated dengue vaccine admixture TV005

The admixtures of the candidate vaccines each contain 4 live attenuated dengue viruses, each of a different serotype.

BIOLOGICAL

Placebo

PLASMA-LYTE A Injection pH 7.4 (Multiple Electrolytes Injection, Type 1, USP) is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration.

Trial Locations (1)

100

National Taiwan University Hospital, Taipei

All Listed Sponsors
collaborator

Centers for Disease Control, Taiwan

OTHER_GOV

lead

National Taiwan University Hospital

OTHER

NCT04133987 - Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan | Biotech Hunter | Biotech Hunter